New drug combo shows promise for hard-to-treat endometrial cancer
NCT ID NCT03008408
First seen Nov 21, 2025 · Last updated Jun 12, 2026 · Updated 28 times
Summary
This study tests whether adding ribociclib to the standard combination of everolimus and letrozole can better control advanced or recurrent endometrial cancer. About 90 participants will receive either two or three drugs to see which approach improves tumor shrinkage or stability. The goal is to find a more effective treatment option for people whose cancer has spread or returned.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.